Insider trade

Director sold ~$467K of REGN shares in the open market

Traded Oct 29, 2025 · Filed Oct 31, 2025

~$467K
Reported value · 712 sh @ $656.50: 2,740
Holds after · shares reported: +12.5%
stock since the trade · S&P 500 +11.1%, $652.91 → $734.81 on Oct 1

Why it stands out

A board member of Regeneron Pharmaceuticals sold $467K of Regeneron Pharmaceuticals shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 29, 2025
Reporting period: Not applicable
Filed with the SEC: Oct 31, 2025

Director$100K–$500K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$467,428

Shares × reported transaction price

Timing vs results

1 day after results of Oct 28, 2025, 75 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $652.91 on Oct 29, 2025, 35% above its 52-week low and 29% below its high, after a 12% rise over the previous 30 trading days

52-week range $483.07 (Jun 5, 2025) to $922.79 (Oct 30, 2024), 39% of the way up, from 250 adjusted closes. 30 trading days earlier: $585.50 on Sep 17, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Libtayo on Oct 29, 2025, the same day as this trade.

New use approved (efficacy supplement). Active ingredient: Cemiplimab-Rwlc. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+1.9%	-0.3%	+2.2%
30 days	+12.7%	+0.1%	+12.6%
90 days	+17.6%	+1.8%	+15.8%
180 days	+10.4%	+5.1%	+5.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001189014-25-000005
Filed / recorded: Oct 31, 2025, 8:09 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: REGENERON PHARMACEUTICALS, INC.
Issuer CIK: 872589
Ticker: REGN
Reporting person: Christine A Poon
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 29, 2025
Transaction code: S
Shares / units: 712
Price per share: $656.50
Acquired / disposed: Disposed (D)
Shares owned after: 2,740
Ownership form: Direct
Amendment: No

Footnotes from the filing

Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.